Recent Videos

BeiGeneius (heme) - Talking head video - RT1 study ASH 2023 - Eichhorst_v2 00:04:42

ASH 2023 updates: RT1 study of tislelizumab plus zanubrutinib in Richter transformation

BeiGeneius (heme) - Talking head video - SEQUOIA+ELEVATE-TN -Tedeschi 00:04:44

ASH 2023 updates: BTK inhibitor monotherapy for treatment-naive CLL

BeiGeneius (heme) - Talking head video - ALPINE ASH 2023 - Tam 00:02:51

ASH 2023 updates: ALPINE study of zanubrutinib vs. ibrutinib in R/R CLL

BeiGeneius (heme) - Talking head video - switching BTKis ASH 2023 - Tam 00:03:05

ASH 2023 updates: Switching BTK inhibitor monotherapy

BeiGeneius (heme) - Talking head video - progression on BTKis ASH 2023 - Tam 00:04:25

ASH 2023 updates: Acquired mutations on BTK inhibitor-containing therapies

BeiGeneius (heme) - Talking head video - fixed-duration therapy for CLL ASH 2023 - Tam 00:05:18

ASH 2023 updates: Fixed-duration therapy for CLL with a BTK plus BCL2 inhibitor

BeiGeneius (heme) - Talking head Video - Wendtner 00:06:11

The 2023 update to the Onkopedia CLL guidelines

BeiGeneius (heme) - Talking head video - BTK inhibition and biomarkers in WM 00:02:33

The role of BTK inhibitors and genetic testing in Waldenström’s macroglobulinemia

BeiGeneius (heme) - Talking head video - Managing tolerability with BTK inhibitors in WM 00:03:18

Managing toxicity with BTK inhibitors in Waldenström’s macroglobulinemia